AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
First Witness Takes Stand in Amgen Biotechnology Patent Case.
Byline: Ronald Rosenberg
May 16--A Whitehead Institute scientist yesterday gave U.S. District Court Judge William Young a primer on biotechnology as he took the stand as the first witness in the patent infringement lawsuit between Amgen Inc. and Transkaryotic Therapies Inc. of Cambridge.
The non-jury trial is being closely watched by Wall Street and the biotechnology community to see how far patents can reach covering a natural substance found in the body and how new, lower-cost manufacturing processes could affect the most profitable biotech drugs.
The suit, which began more than three years ago, stems from TKT's claim that it has found an alternative way to make Epogen, a red-blood cell stimulator developed by Amgen -- and the world's best-selling biotech drug with worldwide sales of nearly $4 billion.
Amgen, based in Thousand Oaks, Calif., has become the nation's largest biotech company because of its success developing and selling Epogen. The company is suing both TKT and its partner, Aventis SA, one of the largest European pharmaceutical companies, for allegedly violating five Amgen patents for Epogen.
- Jury Rules Roche Infringes Amgen's EPO Patents.
- Press release article from: Business Wire October 23, 2007 700+ words
...erythropoietin (peg-EPO) product MIRCERA infringes 11 Amgen EPO patent claims. Amgen is pleased with the jury's verdict and will...Nov. 15, 2007. In addition to infringing its EPO patents, Amgen firmly believes Roche's peg-EPO product provides...
- Federal Judge Denies TKT & HMR Attempt to Dismiss Amgen EPO Patent Suit.
- Press release article from: Business Wire April 16, 1998 700+ words
...Roussel (HMR) to dismiss Amgen's lawsuit for infringement...several U.S. patents owned by Amgen that claim an erythropoietin (EPO) product and processes for...with a trial on the merits. Amgen markets EPO in the United States as EPOGEN...
- A `Wonder Drug' Held Hostage; Dispute Between Amgen, Ortho Delays Patient...
- Newspaper article from: The Washington Post Malcolm Gladwell May 11, 1989 700+ words
...of the marketing rights to EPO. Alleging that Amgen had reneged on the agreement...the FDA to delay approval of Amgen's EPO application until equal consideration...clinical trials on the drug. Amgen, believing that EPO was a relatively modest discovery...
- Sunlight Research™, Releases Its Amgen EPO Patents Report.(Report)
- Newspaper article from: Biotech Week September 30, 2009 700+ words
...announced the release of its report analyzing Amgen, Inc.'s Erythropoietin (EPO) US patent portfolio (see also Biologics...protection of well known biologicals, such as EPO." Sunlight's Amgen EPO patents report includes a detailed breakdown...
- AMGEN PREVAILS OVER TKT, AVENTIS IN EPO PATENT INFRINGEMENT CASE.(Amgen Inc.,...
- Magazine article from: BIOWORLD Today Willett, Matthew January 23, 2001 700+ words
...stage for the evolution of Amgen's EPO franchise in the future...Tang told BioWorld Today Amgen can keep its EPO franchise through the sustained-release EPO product nearing approval, Aranesp. "We expect [Amgen] will be able to convert...
- Sunlight Research(TM), Releases Its Amgen EPO Patents Report.
- Press release article from: PR Newswire September 14, 2009 700+ words
...announced the release of its report analyzing Amgen, Inc.'s Erythropoietin (EPO) US patent portfolio. The Report analyzes...protection of well known biologicals, such as EPO." Sunlight's Amgen EPO patents report includes a detailed breakdown...
- Judge Says Amgen Entitled to Permanent Injunction in EPO Case.
- Magazine article from: BIOWORLD Today Boggs, Jennifer October 6, 2008 700+ words
...these matters," meaning that Amgen's EPO product Epogen (epoetin alfa...that Mircera does not infringe Amgen's EPO patents, said it would agree to...BioWorld Today, Oct. 19, 2004.) Amgen's EPO franchise drugs, which include...
- Genetics Institute seeks summary judgement against Amgen for EPO patent...
- Press release article from: PR Newswire February 4, 1988 700+ words
...SEEKS SUMMARY JUDGEMENT AGAINST AMGEN FOR EPO PATENT INFRINGEMENTT CAMBRIDGE...of Johnson & Johnson -- Amgen's EPO licensee -- with infringement...Background Litigation surrounding EPO was initiated by Amgen in October 1987. The suit charged...